Eisai, Concordia deal

Eisai will sell to Concordia U.S. and Puerto Rican commercialization rights to anticonvulsant Zonegran zonisamide. Eisai will receive $90 million in cash and the companies are expected to close a supply deal under which Eisai will be Concordia's supplier of the product that blocks sodium (Na) and calcium (Ca) channels. Zonegran is available as a generic in the U.S. and Puerto Rico. ...